13046_2021_1909_MOESM2_ESM.pdf (974.52 kB)
Additional file 2 of Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma
journal contribution
posted on 2021-03-25, 08:40 authored by Mitsuhito Hirano, Yoichi Imai, Yuta Kaito, Takahiko Murayama, Kota Sato, Tadao Ishida, Junichi Yamamoto, Takumi Ito, Muneyoshi Futami, Masaki Ri, Hiroshi Yasui, Tamami Denda, Yukihisa Tanaka, Yasunori Ota, Masanori Nojima, Yasuhiko Kamikubo, Noriko Gotoh, Shinsuke Iida, Hiroshi Handa, Arinobu TojoAdditional file 2: Figure S2. Effects of HDAC and Akt inhibitors on MM cell lines. (a) Western blot validation of the effects of ACY-1215 on Akt expression in RPMI8226. (b-d) Prognostic value of GSK-3 α/β and Myc expression based on MM patient clinical trial data. (e) Flow cytometry assay was performed with annexin V/PI staining. (f) U266, (g) H929 CRBN sh#395, (h) KMS-11, (i) KMS-11/BTZ, and (j) MM1.S were treated with DMSO, 2 μM ACY-1215 (ACY), 4 μM afuresertib (Afu), or a combination of ACY-1215 and afuresertib (comb) for 72 h. the average was calculated for each experiment performed in quintuplicate (n = 5). (*p < 0.05, **p < 0.01, “ns” indicates no significant difference).
